HAART to HEART: A multidisciplinary adherence support and evaluation program in Ryan-White funded community health centers

Lisa R Hirschhorn, Susan Goldin, Theresa Meehan, Israel Flores, William Woods, Jeanne Day, Lindsay A Ruhlmann, Judith Steinberg, Laurie M Kunches

Dimock Community Health Center, JSI Research and Training, Neponsett Health Center
Adherence at a CHC

• Dimock Community Health Center (DCHC) urban-based comprehensive CHC with Title IIIb-funded HIV primary and specialty care

• In 1997-8: Dimock Community Health Center (DCHC), 58% of pts on PI did not achieve durable suppression

• Toxicity and side effects were significantly associated with failure
  – (63% vs 30%) and poor adherence (61% vs 41%)
  – 30% of HAART failures were unable to tolerate Rx for 12 weeks

• In a larger study, the most common patient-reported reason for stopping HAART was side effects

JSI Research and Training Institute and Dimock Community Health Center, October 2001
HAART to HEART concept

• For highly ACTIVE antiretroviral therapy (HAART) to be EFFECTIVE, you must be able to access, accept, take, tolerate and adhere

• HAART to HEART, initiated to improve adherence and treatment success by changing highly active antiretroviral therapy into highly effective antiretroviral therapy
Changes in the clinic

• Interventions to improve the durability of PI and HAART response were strengthened to include aggressive side effect and toxicity management

• Efforts included the development of a more aggressive and comprehensive adherence program to improve treatment success (education, adherence, optimal regimen design etc.)

• Target population was ~200 HIV patients in primary care
  – 85% communities of color, 45% women
  – ~60% HCV (+), >75% history of substance abuse and/or mental illness
Program Design

- Multidisciplinary team integrated into HIV primary care clinic
- Educate all team members on treatment, side effects, and management and adherence
- Traditional adherence aids
- Nutritional support
- Mental health counseling
- Peer support and advocacy
- Patient education
Adherence support team

• HIV specialist (team leader)
• PCP (if not the team leader)
• Nurse case manager/educator
• Peer educator/advocate
• Mental health counselor
• Nutritionist
• Psychosocial case manager(s)
• Psychiatrist
• Other (employment specialist, referral coordinator, interpreter)
Design (continued)

• Peers received specialized training in adherence and treatment, and supervision from mental health counselor

• Develop and collect educational materials (English and Spanish) from web and publications to create permanent resources and patient manuals
  – Manual translated into 3 languages and updated regularly as collaboration between DCHC and JSI
Protocol for HAART Initiation

• All patients met with their PCP for initial HAART discussion. Decision and initiation takes 2-3 visits
• After PCP visit, the patient meets with a nurse case manager/educator who reinforces education and provide additional information
• All patients are offered a peer educator. If they accept the peer support, peers contact regularly
• Psychosocial case manager is involved in >70% of cases
• Education and support includes use of a manual, regimen and adherence review, general HIV education, aggressive referrals for mental health, substance abuse, nutrition, psychosocial needs
Results

• Over 75% of patients on HAART engaged in some aspect of the program
  – 85% from communities of color
  – 40% women

• High rates of comorbid conditions (HCV, mental illness, substance abuse) required most to access >1 service and needs changed over time

• Follow-up chart review in 1999 showed that >90% of individuals who achieved viral suppression remained suppressed for >1 year
SPNS and HAART to HEART

• Funded in October 1999 including expansion of adherence program to second CHC and evaluation of efficacy of home-based component
• This has allowed a more intensive look at the program
• Preliminary results from DCHC are presented
Preliminary SPNS data

- 43 patients on HAART enrolled into program and screened for problems with adherence
  - 57% women, 87% communities of color
  - 42% IDU risk, 61% substance abuse, 38% mental illness
- 63% had viral loads below level of detection
- 65% reported 100% 3 day adherence and 56% reported missing < 1 time/week
- Lower levels of HIV-related knowledge was associated with missing doses
- Both substance abuse and difficulty taking medications on time were associated with not achieving undetectable plasma viral load

JSI Research and Training Institute and Dimock Community Health Center, October 2001
Role of Peer Adherence Counselor

• 2 peers hired and trained by the clinic to provide education and adherence support

• In the first 7 months of SPNS evaluation, 46% of enrolled clients accepted a PAC (67% women, 67% minority)

• 2 PACS initiated 168 encounters (range 1-25/client) with 83% resulting in contact by phone or face-to-face

JSI Research and Training Institute and Dimock Community Health Center, October 2001
Role of Peer Continued

• Direct services included education and adherence, but also included referrals for mental health or substance abuse treatment, housing, utilities and advocacy for care and treatment.

• Women had high rates of chaos, with intervention provided in mean of 2.8 areas in addition to adherence and education.
Lessons Learned

• Establishment of a multidisciplinary adherence support program integrated into a CHC HIV primary and specialty care program can be done, but it takes time and effort

• Adherence needs change with time therefore, the program must also be flexible and responsive to needs

• It is hard to collect data

• Peers are an effective and valuable part of the team, but require training to include boundaries, triage and self-support
Future Directions

• Further funding through SPNS grant in collaboration with John Snow and new CHC to continue evaluation
• Continue training in clinic and through NEAETC to ensure state-of-the-art care and side effect management
• Continue to address new challenges: hepatitis C, aging, lipodystrophy, lactic acidosis, etc.
• Continue to monitor effectiveness as people survive longer and medications change